Abstract: The present invention relates to a salt of carvedilol and/or corresponding solvates thereof, compositions containing such carvedilol and/or corresponding solvates thereof, and/or methods of using the aforementioned compound(s) in the treatment of certain disease states in mammals, in particular man. The present invention further relates to carvedilol phosphate salts, and/or solvates thereof, which include a novel crystalline form of carvedilol dihydrogen phosphate (i.e., which is the dihydrogen phosphate salt of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol) and/or carvedilol hydrogen phosphate, etc.) and/or other corresponding solvates thereof, compositions containing these carvedilol phosphate salts and/or solvates, and methods of using the aforementioned salts and/or solvates to treat hypertension, congestive heart failure and angina, etc.

Abstract: The present invention relates to a salt of carvedilol, corresponding compositions containing such a carvedilol salt or corresponding solvates thereof, and/or methods of using the aforementioned compound(s) in the treatment of certain disease states in mammals, in particular man. The present invention further relates to a novel crystalline form of carvedilol hydrobromide, which is the hydrobromide salt of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol, and/or other carvedilol solvates thereof, compositions containing salts or solvates of carvedilol hydrobromide, and methods of using the aforementioned compound(s) to treat hypertension, congestive heart failure, and angina, etc.

Abstract: This invention relates to novel intermediates and processes for preparing pharmaceutically active quinoline compounds, including (?)-(S)—N-(?-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide.

Abstract: This invention relates to a process for preparing eprosartan by reacting 4-[(2-n-butyl-5-formyl-1H-imidazol-1-yl)methyl]benzoic acid or the bisulfite addition compound of 4-[(2-n-butyl-5-formyl-1H-imidazol-1-yl)methyl]benzoic acid with (2-thienylmethyl)propanedioic acid, mono-ethyl ester.

Abstract: New intermediates, namely 2-(2-halo-3,4-dimethoxybenzyl)-5-(4-methoxyphenyl)-oxazolidines, are prepared by a synthetic sequence which uses a Darzen's reaction in a homogeneous solvent system.

Abstract: New intermediates, namely 2-(2-halo-3,4-dimethoxybenzyl)-5-(4-methoxyphenyl)-oxazolidines, are prepared by a synthetic sequence which uses a Darzen's reaction in a homogeneous solvent system.

Abstract: A process for preparing cimetidine by sulfur extrusion from N-cyano-N'-methyl-N"-[2-(5-methyl-4-imidazolylmethyldithio)ethyl]guanidine .

Abstract: A process for preparing cimetidine by sulfur extrusion from N-cyano-N'-methyl-N"-[2-(5-methyl-4-imidazolylmethyldithio)ethyl]guanidine .

Abstract: A method of preparing 2-cyanamidobenzimidazoles or 2-cyanamidobenzoxazoles comprising reacting N-cyanodiphenoxyiminocarbonate with an o-amino or o-hydroxy aniline.

Abstract: N-Phenyl-N'-cyano-O-phenylisoureas are prepared from N-cyanodiphenoxyimidocarbonate and an optionally substituted o-phenylenediamine or o-aminophenol. The isoureas are new chemical intermediates especially useful for preparing 2-cyanamido and 2-carbomethoxyaminobenzimidazole and benzoxazole compounds having anthelmintic activity.

Abstract: New imidazolemethylphosphonium salts having a degradable group at the 2-position which are useful intermediates for preparing histamine H.sub.2 antagonists. This invention concerns the preparation of imidazolemethylphosphonium salts having no substituent at the 2-position by heating the compounds referred to above.

Abstract: New imidazolemethylphosphonium salts having a degradable group at the 2-position which are useful intermediates for preparing histamine H.sub.2 antagonists.